Bone Biologics Corp Cash Flow Statement
BBLG|4 years of annual SEC 10-K data (FY2017-FY2020)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
Bone Biologics Corp used $3M in operating cash flow in FY2020.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|
| Net Income | -$3.4M | -$4.4M | -$7.1M | -$17.0M |
| Depreciation & Amortization | $50 | $96 | $96 | $620 |
| Operating Cash Flow | -$3.3M | -$4.1M | -$3.3M | -$4.6M |